New National System Aims to Test Drugs for Cancer Recurrence in High-Risk Patients

Aparna Raj Parikh shared by Science for America, on X:

” Grateful for a team and community that believes in this mission!”

Quoting Science for America‘s post:

” Scientists at Science for America, Mass General Cancer Center, Genentech, Broad Institute lay out a blueprint in Nature Reviews Cancer for a national system to facilitate routine ‘cancer recurrence interception trials.’

The trials will test new drugs in patients with a high-risk of cancer recurrence, based on the presence of circulating tumor DNA, before clinical or radiographic evidence of recurrence is apparent.

The system could speed drug development for solid cancers — enabling faster, smaller, and cheaper clinical trials by engaging the more than 100,000 patients who have been treated for an early-stage cancer but remain at risk that the cancer will recur.”

Additional information.
Source: Aparna Raj Parikh/X and Science for America/X

Aparna Raj Parikh is a GI oncologist, at Massachusetts General Hospital and associate professor at the Harvard Medical School. She has a long-standing background and interest in global health, having spent time in several African countries, Haiti and India.

Most recently, at MGH, she co-founded and co-leads a program called POETIC (Program for Enhanced Training in Cancer (POETIC)). This fellowship exchange program, conducted in collaboration with Beth Israel Deaconess Medical Center Cancer Center and Lowell Schnipper, MD, trains clinical oncology fellows from the University of Cape Town in South Africa and Ocean Road Cancer Center in Tanzania. She is a member of the OncoDaily Editorial Board.